HDAC inhibitor phenylbutyrate (PBA) was shown to be able to attenuate hippocampal neuronal loss and reverse the Alzheimer’s disease-like phenotype in a mouse model of Alzheimer’s disease [157]. This evidence concerns the gene HDAC9 and early-onset autosomal dominant Alzheimer disease.